<DOC>
	<DOCNO>NCT02169921</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness TurboHawk treatment peripheral arterial disease ( PAD ) superficial femoral and/or popliteal arteries Japanese population .</brief_summary>
	<brief_title>TurboHawk™ Japan Trial Patients With PAD</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Provides write informed consent Willing comply followup evaluation specify time Has Rutherford Clinical Category Score 24 Disease locate within femoropopliteal artery Has evidence ≥ 50 % stenosis occlusion superficial femoral and/or popliteal , confirm angiography Each discrete target lesion 's length ≥4cm ≤ 15 cm Reference vessel diameter ≥ 3.5 mm ≤ 7.0 mm Previously implant stent ( ) stent graft ( ) target leg Life expectancy le 12 month Has plan surgical endovascular intervention target vessel 30 day index procedure Has instent restenosis target lesion Has aneurysmal target vessel Has perforation , dissection injury access target vessel require additional stenting surgical intervention prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>